Read twice and referred to the Committee on Agriculture, Nutrition, and Forestry.
This bill (Agricultural Biotechnology Coordination Act) amends the Department of Agriculture Reorganization Act of 1994 to require the Secretary of Agriculture to establish an Office of Biotechnology Policy within USDA. The Office would be led by a Director reporting to the Secretary (or designee) and would coordinate Department policies and activities relating to biotechnology, biomanufacturing, synthetic biology, and related emerging technologies.
Progressives emphasize the need for public-interest safeguards, transparency, and protections against industry capture; conservatives emphasize limiting federal expansion and regulatory burden.
Relative to its intended legislative type, this bill is a straightforward administrative reorganization that clearly establishes an Office of Biotechnology Policy within USDA with defined high-level duties and interagency/industry consultation requirements.
This bill (Agricultural Biotechnology Coordination Act) amends the Department of Agriculture Reorganization Act of 1994 to require the Secretary of Agriculture to establish an Office of Biotechnology Policy within USDA.
The Office would be led by a Director reporting to the Secretary (or designee) and would coordinate Department policies and activities relating to biotechnology, biomanufacturing, synthetic biology, and related emerging technologies.
The Office’s duties include coordinating research and development, communication/extension/education, regulation and labeling, commercialization/use/trade, assisting other USDA components, interagency coordination (explicitly naming EPA and FDA), and consultation with developers, academics, producers, and other affected entities.
On content alone, this is a modest, administratively focused bill that does not create new entitlements, taxes, or explicit regulatory authority; such organizational measures often succeed because they are limited in scope. However, biotechnology is a moderately contentious policy area, and the Office's potential influence over regulation, labeling, and commercialization could provoke stakeholder and legislative scrutiny. The lack of specified funding and absence of explicit compromise features slightly reduce near-term enactment prospects without further legislative or appropriations action.
Relative to its intended legislative type, this bill is a straightforward administrative reorganization that clearly establishes an Office of Biotechnology Policy within USDA with defined high-level duties and interagency/industry consultation requirements. It integrates into existing statutory text via an insertion and a conforming amendment.
Progressives emphasize the need for public-interest safeguards, transparency, and protections against industry capture; conservatives emphasize limiting federal expansion and regulatory burden.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize the need for public-interest safeguards, transparency, and protections against industry capture; conservatives emphasize limiting federal expansion and regulatory burden.
A mainstream progressive would view the bill as a mixed opportunity: it could strengthen public oversight and coordination of agricultural biotechnology and potentially be used to advance safety, environmental protection, and equitable access to benefits.
However, absent explicit statutory safeguards in the text, they would be wary that the new Office could be oriented toward industry interests, prioritize commercialization over public-interest safeguards, and lack transparency or enforceable protections for communities, the environment, and small producers.
They would likely condition support on additional provisions guaranteeing public engagement, transparency, independent science advisory input, and environmental and civil-rights protections.
A pragmatic moderate would see the bill as a sensible housekeeping and coordination measure that could reduce duplication across USDA and improve regulatory clarity for an increasingly important technology area.
They would welcome clearer interagency lines with EPA and FDA but would be cautious about creating a permanent new bureaucracy without clear authorities, measurable goals, oversight, and a budget.
They would generally favor the bill if it includes accountability, defined performance metrics, and careful cost control.
A mainstream conservative would be skeptical about another expansion of federal bureaucracy and would scrutinize whether the Office will impose new regulatory burdens or labeling mandates that restrict markets and raise costs.
At the same time, they may see potential upside if the Office actively promotes commercialization, trade, and private-sector innovation.
Their support would depend on limiting regulatory overreach, ensuring the Office does not create new compliance costs, and preserving private-sector primacy in development.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, this is a modest, administratively focused bill that does not create new entitlements, taxes, or explicit regulatory authority; such organizational measures often succeed because they are limited in scope. However, biotechnology is a moderately contentious policy area, and the Office's potential influence over regulation, labeling, and commercialization could provoke stakeholder and legislative scrutiny. The lack of specified funding and absence of explicit compromise features slightly reduce near-term enactment prospects without further legislative or appropriations action.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize the need for public-interest safeguards, transparency, and protections against industry capture; conservatives empha…
On content alone, this is a modest, administratively focused bill that does not create new entitlements, taxes, or explicit regulatory auth…
Relative to its intended legislative type, this bill is a straightforward administrative reorganization that clearly establishes an Office of Biotechnology Policy within USDA with defined high-level duties and interagen…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.